Estrogen is named as an intervention in 2 current clinical trials in our China and Canada registers. 1 is recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is The Third Xiangya Hospital of Central South University (1). The most-studied condition is Missed Abortion.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion
NCT07422506 · ClinicalTrials.gov ↗ · Missed Abortion, Early Pregnancy Failure
|
Not applicable | Recruiting | The Third Xiangya Hospital of Central South University | China |
|
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers
NCT02238808 · ClinicalTrials.gov ↗ · Estrogen Receptor Positive Breast Cancer
|
Phase 2 | Active, closed | AHS Cancer Control Alberta | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| The Third Xiangya Hospital of Central South University | 1 |
| AHS Cancer Control Alberta | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Canada registers name Estrogen as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The Third Xiangya Hospital of Central South University (1) and AHS Cancer Control Alberta (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Estrogen works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Estrogen works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Estrogen (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.